Treatment News : Gilead Files Approval Request for Integrase Inhibitor Elvitegravir

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » June 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


June 27, 2012

Gilead Files Approval Request for Integrase Inhibitor Elvitegravir

Gilead Sciences has filed a New Drug Application for elvitegravir, its experimental integrase inhibitor, for use in combination with other antiretrovirals (ARVs) for treatment-experienced people living with HIV, according to a company news announcement.

The filing means Gilead currently has two ARVs under review by the U.S. Food and Drug Administration (FDA). The company’s “Quad” fixed-dose combination tablet—containing elvitegravir, the novel boosting agent cobicistat and the nucleoside reverse transcriptase inhibitors tenofovir and emtricitabine—was recently recommended for approval by the FDA’s Antiviral Drugs Advisory Committee for people living with HIV starting ARV therapy for the first time.

The application for elvitegravir, supporting its use as a separate drug in combination with other HIV medications, is backed by 96-week data from a Phase III study in which once-daily elvitegravir was comparable to Merck’s twice-daily integrase inhibitor Isentress (raltegravir), each administered with a background regimen that included a fully active Norvir (ritonavir)–boosted protease inhibitor and a second ARV.

Approval of elvitegravir could be granted before the end of 2012. The approval of the Quad is expected sometime this summer.

Search: gilead, integrase inhibitor, elvitegravir, fda, nda, approval

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.